Fig. 6: TRAIL–CDK9i is highly effective at killing colorectal cancer patient-derived organoids.
From: Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
a Comparing protein expression analysis on tumor and normal tissues of 20 colorectal patients revealed significantly increased expression of CDK9 in tumor versus normal colorectal tissue. Representative pictures of immunohistochemically determined CDK9 expression on normal human colon tissue and colorectal cancer tissues (left panel). Statistical significance between groups was determined using Wilcoxon signed-rank test for group comparison demonstrated by boxplot. P values of <0.05 were considered statistically significant. b–e Sytox-positive colorectal cancer-derived organoids were treated for 24 h with DMSO, iz-TRAIL (0–10 ng/ml) and/or dinaciclib (25 nM) and/or NVP-2 (25 nM). Scale bars, 200 µm (left panels). Cell viability was quantified after 24 h (right panels). Data are mean ± SEM, n ≥ 3.
